You are here

Use of Thiopurines During Conception and Pregnancy not Associated With Adverse Pregancy Outcomes or Health of Infants at 1 Year in a Prospective Study.

Related Articles Use of Thiopurines During Conception and Pregnancy not Associated With Adverse Pregancy Outcomes or Health of Infants at 1 Year in a Prospective Study. Clin Gastroenterol Hepatol. 2017 Mar 22;: Authors: Kanis SL, de Lima-Karagiannis A, de Boer NK, van der Woude CJ Abstract BACKGROUND & AIMS: Most data on the safety of thiopurine therapy for inflammatory bowel disease (IBD) during pregnancy come from retrospective studies, making it difficult to adjust for confounding factors. We performed a prospective cohort study to determine whether thiopurine use affects pregnancy outcomes…

Read More

Machine Learning Algorithms for Objective Remission and Clinical Outcomes with Thiopurines.

Machine Learning Algorithms for Objective Remission and Clinical Outcomes with Thiopurines. J Crohns Colitis. 2017 Mar 14;: Authors: Waljee AK, Sauder K, Patel A, Segar S, Liu B, Zhang Y, Zhu J, Stidham RW, Balis U, Higgins PD Abstract Background and Aims: Big data analytics leverage patterns in data to harvest valuable information, but are rarely implemented in clinical care. Optimising thiopurine therapy for inflammatory bowel disease [IBD] has proved difficult. Current methods using 6-thioguanine nucleotide [6-TGN] metabolites have failed in randomized controlled trials [RCTs], and have not been used…

Read More

Exposure-Efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease.

Exposure-Efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease. J Crohns Colitis. 2017 Feb 17;: Authors: Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I Abstract Background and Aims: A positive relationship between vedolizumab trough serum concentrations and clinical outcomes in patients with ulcerative colitis (UC) or Crohn’s disease (CD) has been reported. Here we further explore exposure-efficacy relationships for vedolizumab induction therapy in…

Read More

Budesonide Multi-Matrix Is Efficacious for Mesalamine-Refractory, Mild to Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Trial.

Budesonide Multi-Matrix Is Efficacious for Mesalamine-Refractory, Mild to Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Trial. J Crohns Colitis. 2017 Mar 04;: Authors: Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP Abstract Background and Aims.: Safety and efficacy of budesonide multimatrix, an oral extended-release second-generation corticosteroid designed for targeted delivery throughout the colon, was examined for induction of remission in patients with mild to moderate ulcerative colitis refractory to baseline mesalamine therapy. Methods.: A randomized, double-blind, placebo-controlled, multicenter trial…

Read More

Treatment Persistence for Infliximab Versus Adalimumab in Crohn’s Disease: A 14-Year Single-Center Experience.

Treatment Persistence for Infliximab Versus Adalimumab in Crohn’s Disease: A 14-Year Single-Center Experience. Inflamm Bowel Dis. 2017 Mar 16;: Authors: Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-Biroulet L Abstract BACKGROUND: Infliximab (IFX) and adalimumab (ADA) are widely used in the treatment of patients with Crohn’s disease (CD). There are few published data on the treatment persistence of IFX and ADA in patients with CD. METHODS: We aimed to compare the persistence rates of IFX versus ADA as first- and second-line tumor necrosis factor antagonist (anti-TNF), to…

Read More

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

Related Articles Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2017 Mar 20;: Authors: Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M Abstract BACKGROUND: The 52-week safety and efficacy of adalimumab in Japanese patients with moderately to severely active ulcerative colitis were demonstrated in a placebo-controlled phase 2/3 trial. Data from patients who enrolled in the open-label extension study are presented. METHODS: Remission and response…

Read More
<< Go Back